Skip to main content
Premium Trial:

Request an Annual Quote

Mike Gresser, Nicholas Kefalides, Ian Lyons

Oxford Genome Sciences has appointed Mike Gresser to its scientific advisory board, the company said last week. Gresser is currently a visiting scholar at the Molecular Biology Institute at the University of California, Los Angeles.
He served before that as executive director of biochemistry and molecular biology at the Merck Frost Center for Therapeutic Research in Quebec.

SensiGen last week said it has named Nicholas Kefalides to the company’s scientific advisory board.
Kefalides was a professor at the University of Pennsylvania for 26 years, and retired from the school in 2006 as professor emeritus.
The company said Kefalides has since been involved in teaching, research, and writing about his area of expertise: the role of connective tissues and basement membranes in degenerative and infectious diseases.

Stem Cell Innovations has named Ian Lyons chief scientific officer, US, the company said last week.
Lyons was previously research area manager, stem cells, and principal scientist for Invitrogen. Prior to this, he was employed in a variety of positions at BresaGen. He holds a PhD from the University of Melbourne.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.